Wedbush Remains a Buy on Intercept Pharma (ICPT)

By Carrie Williams

In a report issued on February 7, Liana Moussatos from Wedbush maintained a Buy rating on Intercept Pharma (ICPTResearch Report), with a price target of $257.00. The company’s shares closed last Monday at $95.17.

According to, Moussatos is a 2-star analyst with an average return of 0.0% and a 44.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

Currently, the analyst consensus on Intercept Pharma is a Strong Buy with an average price target of $167.42.

See today’s analyst top recommended stocks >>

Based on Intercept Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $84.83 million. In comparison, last year the company had a GAAP net loss of $88.01 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.